{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_codes_code in Code Literal (approximate match)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Codactide is a synthetic octadecapeptide, an analog of adrenocorticotropin. When administered intravenously, codactide produced a prolonged adrenal stimulatory action, as measured by high 11-hydroxycorticosteroid level.
Status:
Investigational
Source:
NCT00203151: Phase 2 Interventional Terminated Systemic Lupus Erythematosus
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Edratide (hCDR1 or TV-4710) is a peptide based on the sequences of the complementarity determining region (CDR) 1 of monoclonal anti-DNA antibody. The capacity of the peptide to bind to major histocompatibility complex class II molecules correlated with the proliferative responses. Edratide is being developed for the treatment of SLE (Systemic Lupus Erythematosus). Edratide ameliorates the SLE-related autoimmune process by specific upstream immunomodulation through the generation of regulatory T cells.
Status:
Investigational
Source:
NCT00545454: Phase 2 Interventional Completed Rheumatoid Arthritis
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03573310: Phase 1 Interventional Active, not recruiting Neoplasms
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04365933: Phase 2 Interventional Completed Hepatitis B, Chronic
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04496349: Phase 2 Interventional Recruiting T-Prolymphocytic Leukemia
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03262389: Phase 2 Interventional Completed Multiple Myeloma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
FLUDEOXYGLUCOSE is a fluorinated glucose analog. Its 18F radiolabelled form is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Status:
Investigational
Source:
NCT02833974: Phase 2 Interventional Completed Asthma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01977443: Phase 2 Interventional Completed Viral Conjunctivitis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03710707: Phase 1 Interventional Completed Parkinson Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GNE0877, aminopyrazole derivative, is a highly potent, selective, brain-penetrable LRRK2 inhibitor and an investigational drug for Parkinson's disease therapy. It inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson’s disease mutation with an IC50 value of 3 nM in vivo. GNE0877 demonstrated metabolic stability, good oral bioavailability (88%) and brain penetration across multiple species.
